FCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. FCCP is often used as an apoptosis inducer.

METHODS: Rat ventricular myocytes were treated with FCCP (10-1000 nM) for 1400 sec, and cellular oxygen consumption was measured using a Clark Oxygen Electrode.
RESULTS: Oxygen consumption increased significantly, immediately, and in a dose-dependent manner after the addition of FCCP. [1]
METHODS: Rat adrenal medullary chromaffinoma cells PC12 were treated with FCCP (30 µM) for 0.5-2 h. The rate of protein synthesis was measured using [3H]methionine.
RESULTS: FCCP treatment produced a strong inhibition (68%) of protein synthesis rate for at least 2 hours. [2]

METHODS: To test the effect on stroke, FCCP (1 mg/kg) was injected intraperitoneally into a C57BL/6J mouse model of stroke, followed by one hour of transient middle cerebral artery occlusion (tMCAO).
RESULTS: Infarct volumes in the cortex, striatum, and whole hemisphere were significantly increased in mice pretreated with FCCP. Mice receiving FCCP had significantly increased neurologic deficit scores compared to carriers. [3]
METHODS: To assay anti-tumor activity in vivo, FCCP (1 mg/kg) and cisplatin (2 mg/kg) were intraperitoneally injected every two days for two weeks into C57BL/6 mice harboring mouse ovarian epithelial carcinoma tumor ID8.
RESULTS: The combination of FCCP and cisplatin inhibited tumor growth via OMA1-induced mitochondrial and ER stress. [4]

Protein synthesis rate is assayed in 24-mm diameter multi-well dishes with fresh medium containing 0.175 Ci/mmol of [3H]methionine (200 μM), for 30 min at 37°C. PC12 cells are treated with FCCP for different period of times. (Only for Reference)